International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
CrossRef
Works that cite this article, indexed by Crossref.
Key safety outcomes of SGLT2 inhibitors versus DPP‐4 inhibitors in general and vulnerable participants with T2DM: A target trial emulation study
Diabetic Medicine (2026)
Chieh‐Li Yen; Pei‐Ru Li; Chao‐Yi Wu; Chung‐Ying Tsai; Jia‐Jin Chen; Chang‐Chyi Jenq; Hsiang‐Hao Hsu; Chang‐Fu Kuo; Lai‐Chu See; Huang‐Yu Yang
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Diabetologia 66(10) (2023)
Matthew Anson; Sizheng S. Zhao; Philip Austin; Gema H. Ibarburu; Rayaz A. Malik; Uazman Alam
Analysis of Prescription Patterns of Antidiabetic Medication in a County From North-Western Romania
Internal Medicine 22(1) (2025)
Cosmin Mihai Vesa
Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report
Journal of Wound Management and Research 21(1) (2025)
Woohyuk Yoon; Joon Ho Lee
Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
Frontiers in Medicine 13 (2026)
Minghui Yin; Hongyi Tan; Shan Xie; Yun Kuang; Qian Wu; Junlong Ma; Chengxian Guo
ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
Advances in Therapy 42(12) (2025)
Rodrigo O. Moreira; Nemencio A. Nicodemus; Abdurrahman Comlekci; Miao Yu; Mussa H. Almalki
Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients
Scientific Reports 13(1) (2023)
Sanghwa Park; Jiseon Jeong; Yunna Woo; Yeo Jin Choi; Sooyoung Shin
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
touchREVIEWS in Endocrinology 17(1) (2021)
Johan H Jendle; Francisco J Ampudia-Blasco; Martin Füchtenbusch; Paolo Pozzilli
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Clinical and Molecular Hepatology 27(2) (2021)
Karn Wijarnpreecha; Elizabeth S. Aby; Aijaz Ahmed; Donghee Kim
Early Use of SGLT2 Inhibitors in Heart Failure With Preserved Ejection Fraction: Quantitative Analysis of Cardiac Biomarkers, Renal Function, and In-Hospital Mortality
Revista de Gestão Social e Ambiental 19(2) (2025)
Luiz Francisco de Souza Neto; Camila Maria Bertão Carvalho; Laura Emilly de Moura Bezerra; Luciano Victor Vasconcelos Saldanha; Artur Freire Brito; Kerolaine Silva Fonseca; Fernando Paniago Santini; Dionéa Ferreira Ayres Viana; Hildo Santiago Reis de Aguiar; Amanda Pinheiro Oliveira; Mariana Mota Benevides de Oliveira; Nelso Gabriel Lippo Turmina; Luis Guilherme Rodrigues de Almeida Moutinho; Rebeca Carvalho Wanderley de Lima Lôbo; Layanna Pessoa Marçal de Oliveira; Raíssa Maria Silvestre Santos; Aurélia Lorena Toscano de Medeiros Borges de Méllo; Levy Alves Pinto Loureiro; Dulce Cerqueira Ferreira Cavalcanti; Ana Clara Onofre Brito Chaves; José Mateus da Silva Bomfim; Ellen Pereira Areal; Maria Eduarda Morales Rodrigues; Rodrigo Porcionato; Joseane Oliveira Braga Nascimento; Harley Davidson Rocha de Lima; Giovana Mendelski Pereira
The Evaluation of Cardiovascular Risk in Diabetic Patients
European Pharmaceutical Journal 69(1) (2022)
S. Kosirova; D. Rubintova; J. Lacka; J. Klimas; T. Foltanova; I. Tumova
Metabolic effects of empagliflozine
Diabetes Obesity Metabolic Syndrome(5) (2022)
Antonina Kedyk; Oleksandr Kutsyn
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
European Endocrinology 1(1) (2021)
Johan H Jendle; Francisco J Ampudia-Blasco; Martin Füchtenbusch; Paolo Pozzilli
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Scientific Reports 15(1) (2025)
Birdie Huang; Chieh-Li Yen; Chao-Yi Wu; Chung-Ying Tsai; Jia-Jin Chen; Ching-Chung Hsiao; Yung-Chang Chen; I-Chang Hsieh; Huang-Yu Yang
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 14 (2021)
Lianglan Shen; Hongli Yang; Xingxing Fang; Huaxing Huang; Wubin Yao; Dongmei Chen; Yan Shen
A practical review of diabetes mellitus type 2 treatment in primary care
Romanian Journal of Internal Medicine 60(1) (2022)
Justin T. Call; Pedro Cortés; Dana M. Harris
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
World Journal of Cardiology 13(12) (2021)
Mouhamed Nashawi; Mahmoud S Ahmed; Toka Amin; Mujahed Abualfoul; Robert Chilton
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
Frontiers in Endocrinology 16 (2025)
Haoyi Yang; Yuwen Zhang; Yuxin Hong; Yuan Wei; Yuning Zhu; Lei Huang; Yuanxun Yang; Runbin Sun; Juan Li
Место ингибиторов натрий - глюкозного котранспортера 2-готипа (SGLT2) в современной медикаментозной терапии сахарного диабета
Medicine: theory and practice 11(1) (2026)
Анна Борисовна Шаповалова; Виктор Владимирович Смирнов; Мигель Анхель Нгуба Муана; Махер Али Хадж Али
Cardiac Remodeling Post-myocardial Infarction: Novel Therapies—Narrative Review
Journal of Clinical Cardiology 7(1) (2026)
Faizan Wadood Siddiqui; Abieyuwa Tari-Ere Oshodin; Manahil Ali; Sherien Metry; Sheima Gaffar; Sawera Gul; Muhammad Ali Muzammil
Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
Acta Diabetologica 63(3) (2025)
Utku Soyaltin; Ilgin Y. Simsir; Baris Akinci